Table 1.
Baseline characteristics (N = 121).
| Characteristics | ||
|---|---|---|
| Age (years) | ||
| Median (range) | 39 | (28–48) |
| Performance status, N (%) | ||
| OMS 0 | 121 | (100%) |
| BMI (kg/m²) | ||
| Median (range) | 22.7 | (17.6–38.6) |
| Genetic status, N (%) | ||
| BRCA1 mutation | 76 | (62.8%) |
| BRCA2 mutation | 31 | (25.6%) |
| Negative or unknown but strong familial history of BOC |
14 | (11.6%) |
| Initial biological information, median (range) | ||
| CA125 (MD = 13) | 15.1 | (4–70.4) |
| FSH (MD = 12) | 5.9 | (0–64.3) |
| Estradiol (MD = 16) | 305 | (1.9–3186) |
| Inhibin B (MD = 24) | 29 | (6–210) |
| AMH (MD = 30) | 5.7 | (0.7–81.4) |
| Family history of breast and ovarian cancer, N (%) | ||
| Any type | 110 | (90.9%) |
| Breast cancer only | 67 | (55.4%) |
| Ovarian cancer only | 7 | (5.8%) |
| Breast and ovarian | 36 | (29.8%) |
| Personal history of breast cancer, N (%) | ||
| Overall | 69 (1)/121 | (57.0%) |
| In BRCA1-mutation carriers | 43/76 | (56.6%) |
| In BRCA2-mutation carriers | 20/31 | (64.5%) |
| In patients with no BRCA1/BRCA2 mutation or unknown status |
6/14 | (42.9%) |
| Prophylactic bilateral mastectomy before RF, N (%) | 30 | (24.8%) |
MD: number of missing data; (1) among the 69 patients who had a personal history of breast cancer, 35 had triple-negative breast cancer (32 in BRCA1 mutation carriers, 2 in BRCA2 mutation carriers, and 1 patient with no BRCA1/2 mutation).